These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 25448250

  • 21. Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis-A simulation analysis.
    Liesenfeld KH, Gruenenfelder F, Clemens A.
    J Clin Pharmacol; 2016 May; 56(5):597-608. PubMed ID: 26272714
    [Abstract] [Full Text] [Related]

  • 22. Treatment of dabigatran-associated bleeding: case report and review of the literature.
    Harinstein LM, Morgan JW, Russo N.
    J Pharm Pract; 2013 Jun; 26(3):264-9. PubMed ID: 23160864
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dose tailoring of dabigatran etexilate: obvious or excessive?
    Douxfils J, Mullier F, Dogné JM.
    Expert Opin Drug Saf; 2015 Aug; 14(8):1283-9. PubMed ID: 25994994
    [Abstract] [Full Text] [Related]

  • 27. Estimation of dabigatran plasma concentrations in the perioperative setting. An ex vivo study using dedicated coagulation assays.
    Douxfils J, Lessire S, Dincq AS, Hjemdahl P, Rönquist-Nii Y, Pohanka A, Gourdin M, Chatelain B, Dogné JM, Mullier F.
    Thromb Haemost; 2015 Apr; 113(4):862-9. PubMed ID: 25519251
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age.
    Abe J, Umetsu R, Kato Y, Ueda N, Nakayama Y, Suzuki Y, Suzuki T, Nagasawa H, Kinosada Y, Nakamura M.
    Int J Med Sci; 2015 Apr; 12(4):312-21. PubMed ID: 25897292
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients.
    Béné J, Saïd W, Rannou M, Deheul S, Coupe P, Gautier S.
    Ann Pharmacother; 2012 Jun; 46(6):e14. PubMed ID: 22669799
    [Abstract] [Full Text] [Related]

  • 34. A Review of and Recommendations for the Management of Patients With Life-Threatening Dabigatran-Associated Hemorrhage: A Single-Center University Hospital Experience.
    Kumar R, Smith RE, Henry BL.
    J Intensive Care Med; 2015 Dec; 30(8):462-72. PubMed ID: 24668159
    [Abstract] [Full Text] [Related]

  • 35. Late rebound of dabigatran levels after idarucizumab reversal in two patients with severe renal failure.
    Stecher A, Vene N, Mavri A, Mijovski MB, Krevel B, Gradišek P.
    Eur J Anaesthesiol; 2017 Jun; 34(6):400-402. PubMed ID: 28459790
    [No Abstract] [Full Text] [Related]

  • 36. Current and emerging strategies in the management of venous thromboembolism: benefit-risk assessment of dabigatran.
    Fanola CL.
    Vasc Health Risk Manag; 2015 Jun; 11():271-82. PubMed ID: 26064057
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Life-threatening bleeding during dabigatran treatment because of acute renal failure].
    Madsen HB, Lütken SC, Povlsen JA, Løfgren B.
    Ugeskr Laeger; 2014 Jun; 176(34):. PubMed ID: 25293571
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.